KATELYN GRIFFIN: Open Payments
NPI 1770012437 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$676 in 38 payments from 18 companies in 2025. Trend: 2023 $410 · 2024 $545 · 2025 $676
Food & beverage: $676
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 7 | $139 |
| AstraZeneca Pharmaceuticals LP | 5 | $75 |
| Amgen Inc. | 5 | $73 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $57 |
| Novartis Pharmaceuticals Corporation | 3 | $49 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $44 |
| Biosense Webster, Inc. | 1 | $40 |
| BridgeBio Pharma, Inc. | 2 | $35 |
| Edwards Lifesciences Corporation | 1 | $26 |
| Bard Peripheral Vascular, Inc. | 1 | $22 |
Products named: VYNDAQEL, REPATHA, FARXIGA, Kerendia, LEQVIO, JARDIANCE, OCTARAY MAPPING CATHETER, Attruby.
Industry payments across AL — which companies pay providers there.
